Eli Lilly’s second quarter of 2026 marked a powerful continuation of its GLP-1 expansion and a further shift from high-growth pharmaceutical company to globally scaled metabolic-health platform. Reported on August 5, with subsequent commentary through August 17–18, the quarter produced approximately $23.0 billion in revenue, up 48% year over year, while adjusted EPS reached $8.38. Revenue exceeded consensus by roughly 11%, and adjusted EPS surpassed expectations by 25%–27.3% 4,5,7,10,11,12,14,15,16,17,18,20,23,25,26.
This was more than a routine earnings beat. Strong patient demand, international expansion, manufacturing investment and a broadening development pipeline are reinforcing one another. The central investment question is therefore evolving. It is no longer simply whether Lilly can grow, but whether it can convert exceptional volume growth into durable earnings while absorbing pricing pressure, capacity spending and a premium valuation.
Key Insights
A broad-based earnings outperformance
The Q2 result is among the most strongly corroborated themes in the available evidence. Six sources support 48% year-over-year revenue growth 9,10,13,15,16,23, while the detailed reported figure was $22.974 billion, compared with $15.558 billion in the prior-year quarter 25. Revenue was substantially above expectations 4,8,10,12,15; one comparison placed sales at $22.97 billion against a $20.62 billion estimate, representing an 11.4% beat 20.
Adjusted EPS of $8.38 rose from $6.31 a year earlier 24 and exceeded the $6.01 consensus in one LSEG survey 14. The reported 25%–27.3% consensus beat is corroborated across multiple sources 18,20. Net income also increased 25%, to approximately $7.10 billion from $5.66 billion 14,16,18,23. Taken together, these figures establish a broad earnings outperformance rather than a revenue-only result.
The GLP-1 formulation remains the principal growth engine
The active pharmaceutical ingredient of Lilly’s growth remains its incretin portfolio, led by Mounjaro and Zepbound. Mounjaro revenue growth has been repeatedly highlighted, including a 125% increase to $8.7 billion in an earlier reported period 2,4,9,10,13,14,16,23. Q2 commentary likewise identifies surging demand for Mounjaro and Zepbound as the central driver of both the quarterly result and the guidance upgrade 20,22,26.
The composition of that growth is particularly important. Global treatment volume increased 60%, while realized prices declined 13% 4,5,7,10,11,12,14,15,16,18,20,23. In the United States, revenue rose 33%, supported by 37% volume growth despite a 3% price decline 14,25. Outside the United States, revenue increased approximately 80%–81% 4,14,23,25, with volume growth of 113% 14. Lilly is therefore still operating in an adoption and access-expansion phase: prescription and treatment-volume growth currently more than compensates for lower net pricing.
International momentum strengthens the case that the opportunity extends beyond the U.S. obesity market. Constant-currency revenue growth reached 55% in Europe, 30% in Japan, 93% in China and 136% in the rest of the world 24. Mounjaro sales outside the United States reached $5.162 billion, approximately 14% above consensus 18. Lilly is also beginning to generate relevant growth beyond its two largest products 23, suggesting that the company may be developing a broader commercial base even as GLP-1 therapies dominate current results.
The formulation of this international opportunity is not without impurities. Non-U.S. volume growth was partly offset by a reported 36% decline in realized prices 14. Geographic diversification improves volume and access, but it does not remove reimbursement and affordability pressure.
Guidance rose, but the EPS ceiling was reduced
The quarter produced a second consecutive increase to Lilly’s 2026 outlook. The most consistently reported revised revenue range is $85 billion–$87 billion, up from $82 billion–$85 billion 10,12. The guidance midpoint increased by approximately $2.5 billion 13,23. Other claims cite an $82 billion–$85 billion range and an $86 billion midpoint 3,9,14,17,18,20,26, which appears to reflect an intermediate or differently defined update.
Adjusted EPS guidance is most consistently reported at $35.50–$36.50 9,14,16,24, although earlier claims cite $35.50–$37.00 1,14,18. Lilly maintained the lower bound at $35.50 while reducing the upper bound from $37.00 to $36.50 18. This is an important qualification to the positive beat-and-raise narrative. Underlying profit guidance improved by $2.78 per share, but that benefit was offset by $3.03 per share in deal-related acquired in-process research and development charges 14,20. Revenue expectations moved higher, while the potential range for reported per-share earnings narrowed at the top.
Strong gross economics, moderated operating conversion
Lilly’s underlying operating quality remains substantial. Q2 gross margin reached 85.8% 23,24, improving by 1.5 percentage points as production costs and product mix improved, partly offset by lower realized prices 25. Free cash flow increased sharply to $7.76 billion from $1.39 billion a year earlier 23.
At the operating level, however, expansion and transactions are imposing a near-term cost. Operating margin declined to 39.1% from 44.1% 20, reflecting higher acquired in-process research and development, restructuring and special charges, as well as increased selling and administrative spending 25. Research and development expense rose to $3.819 billion from $3.336 billion 25, while asset impairment, restructuring and other special charges reached $703 million, compared with zero in the prior-year quarter 25. Lilly therefore has considerable gross-margin and cash-generation capacity, but earnings conversion is being moderated by investment, acquisitions and portfolio-building costs.
Manufacturing capacity is the enabling infrastructure
Supply expansion is a strategic prerequisite, not a discretionary growth initiative. Lilly has committed approximately $55 billion to U.S. manufacturing projects since 2020 18 and invested $5.259 billion in property and equipment during the first six months of 2026 25. It has also announced a further $750 million expansion for injectable-device production 17,19.
New capacity is expected to come online and help resolve constraints that previously limited growth 10,23. This investment should allow Lilly to capture more of the underlying demand for GLP-1 medicines, but the manufacturing process reveals a corresponding set of risks. Production expansion requires substantial expenditures 23, creating execution, capital-allocation and operating-leverage considerations. Management’s expectation that new capacity and pipeline assets will enter the portfolio through business development 18 reinforces the company’s ambition while increasing exposure to acquisition costs and development risk. Quality cannot be rushed; capacity must be commissioned at the required scale without compromising supply-chain integrity or product quality.
Competitive position and pipeline optionality
The competitive backdrop remains favorable. Lilly has been gaining market share against Novo Nordisk 23, and the contrasting guidance narratives—Lilly raising its outlook while Novo Nordisk was reported as lowering guidance—suggest relative commercial momentum for Lilly 23. The broader sector is also constructive: 16 of the 25 largest drugmakers raised 2026 sales guidance 13. Some of the positive pharmaceutical-sector tone is therefore not unique to Lilly.
Lilly’s combination of obesity and diabetes demand, international growth, high margins and a strong pipeline nevertheless supports a differentiated position. Analysts forecast annual earnings growth of approximately 16.6% 17 and pharmaceutical-segment earnings growth of 18.8% 17. Leerink raised its 2027 adjusted EPS estimate from $49.28 to $52.34 and its price target from $1,232 to $1,309 18.
The pipeline provides meaningful optionality, but it should not be treated as equivalent to commercialized GLP-1 earnings. Lilly reported positive Phase III results, new indications, additional pipeline medicines and expanded patient access 24, while continuing Phase III and new-trial activity 25. Management plans to invest in next-generation therapies and remain opportunistic but disciplined in business development 16,24. A CHMP opinion concerning portfolio expansion represents another regulatory catalyst, although the precise product and commercial impact are not specified 24. Clinical, regulatory, acquisition and market-uptake uncertainties remain material 25.
Valuation has less room for error
Fundamental enthusiasm is tempered by valuation and price action. Lilly’s market capitalization was approximately $1.054 trillion in August 2026 21, and its shares had gained 52.7% over the preceding year 26, despite a roughly 5% decline over the prior 30 days 19. After the earnings release, the stock initially rose approximately 4%–5% 9,26, climbed from $1,115.68 to $1,192.28 during the week, and then closed at $1,185.71 after profit-taking 18.
Technical commentary identified support near $1,115.88 and the Bollinger middle band around $1,177, while a move above $1,235.56 was viewed as upside confirmation 23. The average analyst price target was approximately $1,292, implying about 9%–10.5% upside; the highest target was $1,600 23,26. These figures indicate that the market already capitalizes much of the growth thesis. A reported premium of just under 10% to consensus valuation and limited tolerance for disappointment 23 are consistent with the risk of stronger second-half price pressure 23.
Pricing, reimbursement and balance-sheet pressure
Pricing is the clearest fundamental counterweight to demand. Global realized prices fell 13% 4,16. U.S. pricing declined 3% overall and 9% excluding changes to rebate and discount estimates 24. Lilly also faces broader reimbursement, drug-price reporting, litigation and pricing-access risks 25. Sales-rebate and discount liabilities increased to $21.122 billion at June 30, 2026, from $17.382 billion at year-end 2025 25.
These pressures are currently being overwhelmed by volume, but the sensitivity is high. If volume growth moderates before manufacturing scale and market access fully offset lower net prices, revenue growth and margins could decelerate quickly. The balance sheet also warrants monitoring: long-term debt rose to $47.858 billion from $40.868 billion 25, while total debt was reported at $54.9 billion, up $12.4 billion 25. Retained earnings increased to $31.893 billion 25, providing an important counterpoint but not eliminating the need for disciplined capital allocation.
Implications for Investors
The cluster describes a reinforcing cycle of demand, capacity, internationalization and pipeline development. GLP-1 demand is generating extraordinary volume growth and repeated guidance increases. That growth is funding manufacturing expansion and investment in follow-on therapies; greater capacity should reduce supply constraints and broaden access; and international launches provide additional runway as the U.S. market encounters pricing and reimbursement pressure. The result is pharmaceutical-sector-leading economics, including a reported Q2 gross margin of 85.8% 23,24 and a 2025 EBIT margin of 45.6%, compared with an estimated industry range of 25%–35% 23.
The essential analytical distinction is between demand durability and earnings durability. Demand appears robust and internationally extensible, but price erosion, rebates and discounts are already visible. The 60% increase in volume alongside a 13% decline in price 4,16 demonstrates that Lilly’s current model depends on a substantial volume-growth cushion. Manufacturing investments and the expanding pipeline can extend that cushion, but they may weigh on near-term operating margins and leverage. The reduction in the EPS guidance ceiling despite the revenue upgrade is an early indication that commercial momentum does not automatically translate into uninterrupted per-share earnings growth 18.
The investment conclusion is constructive but valuation-sensitive. Lilly’s trajectory supports a premium to traditional pharmaceutical peers, given its market-share gains, high margins, repeated earnings beats and estimated 16.6% earnings growth 17,26. Yet the shares are already up more than 50% over 12 months 26, and consensus upside is generally limited to the single digits 23. Further appreciation is therefore likely to require continued positive revisions: stronger international Mounjaro uptake, successful capacity commissioning, sustained volume growth despite price pressure, or meaningful pipeline de-risking.
Investors should look beyond headline revenue beats, which are now well established, and examine the purity of earnings conversion. The most informative indicators will be net pricing, rebate development, operating-margin recovery, manufacturing execution, debt growth and the extent to which non-GLP-1 assets broaden the earnings base.
Data consistency and interpretation
The dominant reporting set supports Q2 revenue near $23 billion and full-year revenue guidance of $85 billion–$87 billion 4,5,7,10,11,12,14,15,16,17,18,20,23,25,26. Isolated claims cite alternative full-year ranges of $82 billion–$85 billion 3,9,14,17,18,26 or $46.4 billion–$47.2 billion 6. The latter is inconsistent with the prevailing 2026 reporting set and should be treated as an outlier or as a reference to a different forecast basis.
Dividend claims also vary between an upcoming $1.73 per-share dividend 17 and $3.46 per share declared for the second quarter 25, likely reflecting different declaration or aggregation conventions. These conflicts do not alter the central operating conclusion, but they limit confidence in using every isolated figure for valuation without reconciling it to Lilly’s official filings.
Key Takeaways
- Q2 2026 confirmed a powerful and well-corroborated GLP-1 growth engine: revenue rose 48% to approximately $23 billion, while adjusted EPS of $8.38 materially exceeded consensus 4,5,7,10,11,12,14,15,16,17,18,20,23,25,26.
- International volume and market expansion are extending the opportunity, but global price declines, higher rebates and reimbursement pressure are the principal threats to earnings durability 4,14,16,23,25.
- Lilly’s manufacturing and pipeline investments can sustain growth and address supply constraints, but they are increasing capital requirements, deal charges, debt and near-term margin volatility 17,18,23,25.
- The fundamental outlook remains strong, yet the share price and valuation already discount substantial success. Incremental upside depends on continued estimate revisions and evidence that volume growth can outpace price erosion 23.